Literature DB >> 8645828

Cystic fibrosis: pathogenesis, pulmonary infection, and treatment.

R B Moss1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8645828     DOI: 10.1093/clinids/21.4.839

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  16 in total

1.  Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.

Authors:  Juyan Zhou; Yunhua Chen; Setareh Tabibi; Luis Alba; Elizabeth Garber; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

2.  Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth.

Authors:  Mark P Rogan; Leah R Reznikov; Alejandro A Pezzulo; Nicholas D Gansemer; Melissa Samuel; Randall S Prather; Joseph Zabner; Douglas C Fredericks; Paul B McCray; Michael J Welsh; David A Stoltz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

3.  Pseudomonas aeruginosa and cystic fibrosis: Antibiotic therapy and the science behind the magic.

Authors:  N E Macdonald
Journal:  Can J Infect Dis       Date:  1997-11

4.  In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens.

Authors:  U Schwab; P Gilligan; J Jaynes; D Henke
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis.

Authors:  E Caballero; M E Drobnic; M T Pérez; J M Manresa; A Ferrer; R Orriols
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 7.  Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Authors:  Sabina Schmitt-Grohé; Stefan Zielen
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

8.  Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.

Authors:  Gabrielle Pilcer; Thami Sebti; Karim Amighi
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

9.  Airway colonization by Acrophialophora fusispora in patients with cystic fibrosis.

Authors:  Bernard Cimon; Svetlana Challier; Hugues Béguin; Jacqueline Carrère; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

10.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.